Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation

References

• Awaad Y, Rizk T. Spasticity in children. J Taibah Univ Med Sci. 2012;7(2):53–60.
   Google Scholar
• Bar-On L, Molenaers G, Aertbelien E, et al. Spasticity and its contribution to hypertonia in cerebral palsy. Biomed Res Int. 2015;2015:317047–317010.
   PubMed Web of Science ®Google Scholar
• Tilton A, Vargus-Adams J, Delgado M. Pharmacologic treatment of spasticity in children. Semin Pediatr Neurol. 2010;17(4):261–267.
   PubMed Web of Science ®Google Scholar
• Makki D, Duodu J, Nixon M. Prevalence and pattern of upper limb involvement in cerebral palsy. J Child Orthop. 2014;8(3):215–219.
   PubMedGoogle Scholar
• Schwabe AL. Botulinum toxin in the treatment of pediatric upper limb spasticity. Semin Plast Surg. 2016;30(1):24–28.
   PubMed Web of Science ®Google Scholar
• Colver A, Fairhurst C, Pharoah P. Cerebral palsy. Lancet. 2014;383(9924):1240–1249.
   PubMed Web of Science ®Google Scholar
• Graham H, Rosenbaum P, Paneth N, et al. Cerebral palsy. Nat Rev Dis Primers. 2016;2(1):15082.
   PubMed Web of Science ®Google Scholar
• Cardoso E, Rodrigues B, Lucena R, et al. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr. 2005;63(1):30–33.
   PubMed Web of Science ®Google Scholar
• Santamato A. Safety and efficacy of incobotulinumtoxin A as a potential treatment for poststroke spasticity. Neuropsychiatr Dis Treat. 2016;12:251–263.
   PubMed Web of Science ®Google Scholar
• Thakker M, Rubin P. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin. 2004;44(3):147–163.
   PubMedGoogle Scholar
• Chung C, Chen C, Wong A. Pharmacotherapy of spasticity in children with cerebral palsy. J Formos Med Assoc. 2011;110(4):215–222.
   PubMed Web of Science ®Google Scholar
• Delgado MR, Tilton A, Carranza‐Del Río J, et al. Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study. Developmental Medicine & Child Neurology. 2020
   Web of Science ®Google Scholar
• Dysport powder for solution for injection. 2020. Available from: https://www.medicines.org.uk/emc/product/7261/smpc. [cited 2020 Oct 12].
   Google Scholar
• Botox powder for solution for injection. 2020. Available from: https://www.medicines.org.uk/emc/product/859/smpc. [cited 2020 Oct 12].
   Google Scholar
• Xeomin powder for solution for injection. 2020. Available from: https://www.medicines.org.uk/emc/product/6202/smpc. [cited 2020 Oct 12].
   Google Scholar
• Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818–1826.
   PubMed Web of Science ®Google Scholar
• Brockmann K, Schweitzer K, Beck G, et al. Comparison of different preparations of botulinum toxin A in the treatment of cervical dystonia. Neurol Asia. 2012;17(2):115–119.
   Web of Science ®Google Scholar
• National Collaborating Centre for Women’s and Children’s Health. Spasticity in children and young people with non-progressive brain disorders: management of spasticity and co-existing motor disorders and their early musculoskeletal complications. Clinical guideline 145. London: RCOG Press; 2016.
   Google Scholar
• Royal College of Physicians. Spasticity in adults: management using botulinum toxin. London: Royal College of Physicians; 2012.
   Google Scholar
• Andringa A, van de Port I, van Wegen E, et al. Effectiveness of botulinum toxin treatment for upper limb spasticity poststroke over different ICF domains: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2019;100(9):1703–1725.
   PubMed Web of Science ®Google Scholar
• Baker J, Pereira G. The efficacy of botulinum toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clin Rehabil. 2013;27(12):1084–1096.
   PubMed Web of Science ®Google Scholar
• Fu X, Wang Y, Wang C, et al. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clin Rehabil. 2018;32(6):713–721.
   PubMed Web of Science ®Google Scholar
• Guyot P, Kalyvas C, Mamane C, et al. Botulinum toxins type A (Bont-A) in the management of lower limb spasticity in children: a systematic literature review and Bayesian network meta-analysis. J Child Neurol. 2019;34(7):371–381.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Danchenko N, Hansen R, et al. Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada. J Med Econ. 2020;23(6):631–640.
   PubMed Web of Science ®Google Scholar
• Rehab measure: Ashworth scale/modified Ashworth scale Rehabilitation Institute of Chicago; 2013. Available from: http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=902.
   Google Scholar
• Higgins J, Sterne J, Savović J, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev. 2016;10:29.
   Web of Science ®Google Scholar
• Danchenko N, Delgado D, Haeussler K, et al. PND10 INDIRECT TREATMENT COMPARISON OF BOTULINUM TOXINS A FOR THE TREATMENT OF PEDIATRIC UPPER LIMB SPASTICITY. Value Health. 2020;23:S260.
   PubMed Web of Science ®Google Scholar
• Khan RA, Sharma N, Saini M, et al. PND14 QUALITY ASSESSMENT OF META-ANALYSES ON INTERVENTIONS FOR BELL’S PALSY USING AMSTAR 2. Value Health. 2020;23:S260–S261.
   PubMed Web of Science ®Google Scholar
• Fehlings D, Gormley M, Kim H, et al. Efficacy and safety of OnabotulinumtoxinA for the treatment of pediatric upper limb spasticity: primary results. Ann Neurol. 2018.
   Web of Science ®Google Scholar
• Bucher H, Guyatt G, Griffith L, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton A, Ades A, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–617.
   PubMed Web of Science ®Google Scholar
• Leonard T, Duffy JC. A Bayesian fixed effects analysis of the Mantel-Haenszel model applied to meta-analysis. Stat Med. 2002;21(16):2295–2312.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Turner-Stokes L, Ashford S, Fheodoroff K, et al. The GAS-eous Tool. Goal attainment scaling - evaluation of outcome for upper-limg spasticity. 2013. Available from: https://www.kcl.ac.uk/cicelysaunders/attachments/tools-gaseous-gaseous-tool.pdf
   Google Scholar
• Fehlings D, Rang M, Glazier J, et al. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr. 2000;137(3):331–337.
   PubMed Web of Science ®Google Scholar
• Lowe K, Novak I, Cusick A. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol. 2006;48(3):170–175.
   PubMed Web of Science ®Google Scholar
• Speth LA, Leffers P, Janssen-Potten YJ, et al. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol. 2005;47(7):468–473.
   PubMed Web of Science ®Google Scholar
• Tonmukayakul U, Le LK-D, Mudiyanselage SB, et al. A systematic review of utility values in children with cerebral palsy. Qual Life Res. 2019;28(1):1–12.
   PubMed Web of Science ®Google Scholar
• Doan QV, Brashear A, Gillard PJ, et al. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM R. 2012;4(1):4–10.
   PubMedGoogle Scholar
• British National Formulary [Internet]. British Medical Association and Royal Pharmaceutical Society of Great Britain; 2020 [cited 2020 Jan 10]. Available from: https://bnf.nice.org.uk/.
   Google Scholar
• Non-mandatory prices 2019-20. National Tariff. [cited 2020 Sep 8]. Available from: https://improvement.nhs.uk/resources/national-tariff/#h2-201920-national-tariff-payment-system
   Google Scholar
• Johnston KM, Danchenko N, Lundkvist J. Resource use related to cervical dystonia, pediatric lower limb spasticity and adult upper limb spasticity in the UK: a physician questionnaire. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research 2020; Virtual USA (May 18-20).
   Google Scholar
• Jacinto J, Ashford S, Fheodoroff K, et al. Real-life data on the time to retreatment with botulinum toxin A in upper limb spasticity management. Virtual congress 7-11 October 2020. World Congress for NeuroRehabilitation. 2020.
   Google Scholar
• Doan QV, Gillard P, Brashear A, et al. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Eur J Neurol. 2013;20(5):773–780.
   PubMed Web of Science ®Google Scholar
• Fehlings D, Gormley M, Kim H, et al. Efficacy and safety of onabotulinumtoxinA for treatment of pediatric upper limb spasticity: primary results. Toxicon. 2018;156:S33.
   Web of Science ®Google Scholar
• Reference Cost Collection: National Schedule of Reference Costs - Year 2017-18 - NHS trust and NHS foundation trusts 2020.
   Google Scholar
• Curtis L, Burns A. Unit costs of health and social care 2019. Canterbury (UK): University of Kent; 2019.
   Google Scholar
• Ward A, Roberts G, Warner J, et al. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med. 2005;37(4):252–257.
   PubMed Web of Science ®Google Scholar
• Doan QV, Brashear A, Gillard PJ, et al. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. Pm R. 2012;4(1):4–10.
   PubMedGoogle Scholar
• Carroll A, Downs S. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr. 2009;155(1):21e21–25e25.
   Web of Science ®Google Scholar
• Chang E, Ghosh N, Yanni D, et al. A review of spasticity treatments: pharmacological and interventional approaches. Crit Rev Phys Rehabil Med. 2013;25(1-2):11–22.
   PubMedGoogle Scholar
• Matza LS, Deger KA, Vo P, et al. Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. Qual Life Res. 2019;28(9):2359–2372.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Slejko JF, Mark J, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal; 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case.
   Google Scholar
• Koman L, Smith B, Williams R, et al. Upper extremity spasticity in children with cerebral palsy: a randomized, double-blind, placebo-controlled study of the short-term outcomes of treatment with botulinum A toxin. J Hand Surg Am. 2013;38(3):435–446.e431.
   PubMed Web of Science ®Google Scholar
• Russo R, Crotty M, Miller M, et al. Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial. Pediatrics. 2007;119(5):e1149–e1158.
   PubMed Web of Science ®Google Scholar
• Wallen M, O'Flaherty S, Waugh M. Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil. 2007;88(1):1–10.
   PubMed Web of Science ®Google Scholar
• Hoare B, Imms C, Villanueva E, et al. Intensive therapy following upper limb botulinum toxin A injection in young children with unilateral cerebral palsy: a randomized trial. Dev Med Child Neurol. 2013;55(3):238–247.
   PubMed Web of Science ®Google Scholar
• Kawamura A, Campbell K, Lam-Damji S, et al. A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity. Dev Med Child Neurol. 2007;49(5):331–337.
   PubMed Web of Science ®Google Scholar
• Pieber K, Herceg M, Wick F, et al. Functional electrical stimulation combined with botulinum toxin type A to improve hand function in children with spastic hemiparesis - a pilot study. Wien Klin Wochenschr. 2011;123(3-4):100–105.
   PubMed Web of Science ®Google Scholar
• Fehlings D, Gormley M, Kim H, et al. Efficacy and safety of onabotulinumtoxinA for the treatment of pediatric upper limb spasticity: primary results. Dev Med Child Neurol. 2018;60(S3):33–34.
   Google Scholar
• Olesch C, Greaves S, Imms C, et al. Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: a randomized controlled trial. Dev Med Child Neurol. 2010;52(1):79–86.
   PubMed Web of Science ®Google Scholar
• Rameckers E, Speth L, Duysens J, et al. Botulinum toxin-A in children with congenital spastic hemiplegia does not improve upper extremity motor-related function over rehabilitation alone: a randomized controlled trial. Neurorehabil Neural Repair. 2009;23(3):218–225.
   PubMed Web of Science ®Google Scholar
• Hu W, Rundle-Gonzalez V, Kulkarni S, et al. Synergistic effects of botulinum toxin and physical therapy in primary cervical dystonia. Neurol. 2016;86(Suppl 16).
   Google Scholar
• Marciniak CM, Harvey RL, Gagnon CM, et al. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity? A randomized, double-blind, placebo-controlled trial. Am J Phys Med Rehabil. 2012;91(12):1007–1019.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. Efficacy and safety of dysport in the treatment of upper limb spasticity in children (PUL). [cited 2020 Jun 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02106351.
   Google Scholar
• Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8–14.
   PubMedGoogle Scholar
• Marque P, Gracies J, Brashear A, et al. Duration of effect of abobotulinumtoxinA (Dysport®) in adult patients with upper limb spasticity (ULS) post-stroke or traumatic brain injury (abstract P043). Ann Phys Rehabil Med. 2017;60(Supplement):e24–e25.
   Google Scholar
• Al-Mazraawy B, Saliba L, Szydlik E, et al. Botulinum toxin usage evaluation and potential cost savings across a five-hospital health system. Paper presented at: 53rd Annual ASHP Midyear Clinical Meeting 2018; Aneheim, CA.
   Google Scholar
• Eckwright D, Burke J, Gleason P. Real-world botulinum toxin utilization and treatment cost for cervical dystonia and limb spasticity among 15 million commercially insured members. Poster presented at the Academy of Managed Care Pharmacy Nexus. 2019.
   Google Scholar
• Bandholm T, Jensen BR, Nielsen LM, et al. Neurorehabilitation with versus without resistance training after botulinum toxin treatment in children with cerebral palsy: a randomized pilot study. Neurorehabil. 2012;30(4):277–286.
   PubMed Web of Science ®Google Scholar
• Elvrum A-KG, Braendvik SM, Saether R, et al. Effectiveness of resistance training in combination with botulinum toxin-A on hand and arm use in children with cerebral palsy: a pre-post intervention study. BMC Pediatr. 2012;12(1):91.
   PubMed Web of Science ®Google Scholar
• Lidman GRM, Nachemson AK, Peny-Dahlstrand MB, et al. Long-term effects of repeated botulinum neurotoxin A, bimanual training, and splinting in young children with cerebral palsy. Dev Med Child Neurol. 2020;62(2):252–258.
   PubMed Web of Science ®Google Scholar
• Williams SA, Elliott C, Valentine J, et al. Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength. Disabil Rehabil. 2013;35(7):596–605.
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Jacinto J, Fheodoroff K; Upper Limb International Spasticity (ULIS-III) study group, et al. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: findings from the prospective, observational upper limb international spasticity (ULIS-III) cohort study. J Rehabil Med. 2021;53(2):jrm00157.
   PubMed Web of Science ®Google Scholar
• Data on file. ENGAGE Study. 2021.
   Google Scholar
• Marsili L, Bologna M, Jankovic J, et al. Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. Expert Opin Drug Saf. 2021;20(6):695–705.
   PubMed Web of Science ®Google Scholar
• Naumann M, Albanese A, Heinen F, et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006;13 Suppl 4(Suppl 4):35–40.
   PubMed Web of Science ®Google Scholar